目的:评价血小板-淋巴细胞比(PLR)与宫颈癌患者远期生存指标的关系,以期为临床判断患者预后提供有力证据。方法:计算机检索PubMed、the Cochrane Library、Web of Science、CNKI、CBM、维普数据库,检索时限均从建库开始至2020年5月31日...目的:评价血小板-淋巴细胞比(PLR)与宫颈癌患者远期生存指标的关系,以期为临床判断患者预后提供有力证据。方法:计算机检索PubMed、the Cochrane Library、Web of Science、CNKI、CBM、维普数据库,检索时限均从建库开始至2020年5月31日。查找血小板-淋巴细胞比与宫颈癌患者远期生存资料相关的病例对照研究。采用NOS对纳入的研究进行质量评价,采用STATA 12.0进行Meta分析。结果:共纳入了10项病例对照研究,共计3426例。Meta分析结果显示,PLR越高宫颈癌患者总生存期(OS)(HR=1.39,95%CI:1.18~1.64,P=0.001)与无进展生存期(PFS)(HR=1.46,95%CI:1.20~1.76,P=0.001)越差,差异具有统计学意义。结论:PLR越高宫颈癌患者远期生存结局越差,PLR具有准确、简单易得的特点,可作为预测宫颈癌患者预后的有效指标。展开更多
Background:Long non-coding RNAs(lncRNAs)have been applied as biomarkers in many diseases.However,scarce biomarkers are available in single lncRNA differential expression associated with different clinical stages of li...Background:Long non-coding RNAs(lncRNAs)have been applied as biomarkers in many diseases.However,scarce biomarkers are available in single lncRNA differential expression associated with different clinical stages of liver cirrhosis(LC).The aim of the study is to identify some lncRNAs that can serve as non-invasive sensitive biomarkers for early diagnosis and grade of LC.Methods:Blood lncRNA expression was evaluated in three independent cohorts with 305 participants including healthy controls,hepatitis B virus(HBV)carriers,and patients with chronic hepatitis B(CHB)or LC.First,candidate lncRNAs were screened by CapitalBiotech microarray to diagnose cirrhosis.Quantitative reverse-transcriptase polymerase chain reaction was then used to investigate the expression of selected lncRNAs in the whole group of cirrhosis and different Child–Pugh classes.Ultimately,the diagnostic accuracy of the promising biomarker was examined and validated via Mann–Whitney test and receiver-operating characteristics analysis.Results:Lnc-TCL6 was identified as a sensitive biomarker for early diagnosis of LC(Child–Pugh A)compared with healthy controls(area under the ROC curve[AUC]=0.636),HBV carriers(AUC=0.671),and CHB patients(AUC=0.672).Furthermore,lnc-TCL6 showed a favourable capacity in discriminating among different Child–Pugh classes(AUC:0.711–0.837).Compared with healthy controls,HBV carriers,and CHB patients,the expression of lnc-TCL6 was obviously up-regulated in Child–Pugh A patients and,conversely,significantly down-regulated in Child–Pugh C patients.Conclusions:Lnc-TCL6 is a novel potential biomarker for early diagnosis of LC and is a possible predictor of disease progression.展开更多
基金supported in part by grants from the National Natural Science Foundation of China[U1501224]the Natural Science Foundation Team Project of Guangdong Province[2018B03031200]+1 种基金the Science and Technology Developmental Foundation of Guangdong Province[2017B020226003]the Science and Technology Program of Guangzhou City[201604020118].
文摘Background:Long non-coding RNAs(lncRNAs)have been applied as biomarkers in many diseases.However,scarce biomarkers are available in single lncRNA differential expression associated with different clinical stages of liver cirrhosis(LC).The aim of the study is to identify some lncRNAs that can serve as non-invasive sensitive biomarkers for early diagnosis and grade of LC.Methods:Blood lncRNA expression was evaluated in three independent cohorts with 305 participants including healthy controls,hepatitis B virus(HBV)carriers,and patients with chronic hepatitis B(CHB)or LC.First,candidate lncRNAs were screened by CapitalBiotech microarray to diagnose cirrhosis.Quantitative reverse-transcriptase polymerase chain reaction was then used to investigate the expression of selected lncRNAs in the whole group of cirrhosis and different Child–Pugh classes.Ultimately,the diagnostic accuracy of the promising biomarker was examined and validated via Mann–Whitney test and receiver-operating characteristics analysis.Results:Lnc-TCL6 was identified as a sensitive biomarker for early diagnosis of LC(Child–Pugh A)compared with healthy controls(area under the ROC curve[AUC]=0.636),HBV carriers(AUC=0.671),and CHB patients(AUC=0.672).Furthermore,lnc-TCL6 showed a favourable capacity in discriminating among different Child–Pugh classes(AUC:0.711–0.837).Compared with healthy controls,HBV carriers,and CHB patients,the expression of lnc-TCL6 was obviously up-regulated in Child–Pugh A patients and,conversely,significantly down-regulated in Child–Pugh C patients.Conclusions:Lnc-TCL6 is a novel potential biomarker for early diagnosis of LC and is a possible predictor of disease progression.
